NEWTOWN, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) — The law firm of Edelson Lechtzin LLP reminds investors who purchased Enochian Biosciences Inc. (“Enochian” or the “Company”) (NASDAQ: ENOB) common stock between February 16, 2018, and June 27, 2022, inclusive (the “Class Period”), of the fast-approaching deadline to file a motion asking the U.S. District Court for the Central District of California to appoint them as lead plaintiff.
Investors who purchased Enochian stock during the Class Period have until September 26, 2022 to select counsel and move for appointment as a lead plaintiff. The lead plaintiff acts as a representative for other class members in directing the litigation. If you continue to hold Enochian shares and wish to discuss your legal options, please contact Edelson Lechtzin LLP, toll free at 1-844-696-7492, or by email at firstname.lastname@example.org.
Background on the Enochian Biosciences Securities Class Action
The Complaint alleges that Enochian, a pre-clinical stage biotechnology company, through its senior officers, made false and misleading statements and material omissions concerning the Company’s financial performance and future prospects. Specifically, it is alleged that Enochian co-founder Gumrukcu was engaged in a variety of fraudulent misconduct, including that he was not a licensed doctor and the scientific and technological underpinnings of Enochian’s product pipeline, purportedly invented by Gumrukcu, were dubious at best….